Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report)'s share price passed above its fifty day moving average during trading on Monday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The stock has a fifty day moving average of $22.04 and traded as high as $23.75. Damora Therapeutics, Inc. Common Stock shares last traded at $22.50, with a volume of 1,232,736 shares.
Several other brokerages also recently issued reports on DMRA. HC Wainwright restated a "buy" rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Guggenheim initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, November 6th. They set a "buy" rating and a $59.00 target price for the company. Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, September 29th. Jefferies Financial Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a "buy" rating and a $50.00 price target for the company. Finally, TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research report on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $46.38.
Get Our Latest Stock Report on DMRA
Insider Activity
In related news, CEO Jennifer Jarrett purchased 12,500 shares of the firm's stock in a transaction dated Friday, September 25th. The shares were acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the completion of the purchase, the chief executive officer directly owned 512,500 shares of the company's stock, valued at $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.40% of the stock is owned by corporate insiders.
Institutional Trading of Damora Therapeutics, Inc. Common Stock
A number of large investors have recently made changes to their positions in the company. Arizona State Retirement System acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth about $260,000. Squarepoint Ops LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth about $303,000. Seven Fleet Capital Management LP acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at approximately $7,398,000. Bellevue Group AG raised its position in Damora Therapeutics, Inc. Common Stock by 18.6% in the 3rd quarter. Bellevue Group AG now owns 1,919,383 shares of the company's stock valued at $40,844,000 after buying an additional 300,537 shares during the last quarter. Finally, Braidwell LP acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at approximately $42,146,000. Institutional investors own 14.20% of the company's stock.
Damora Therapeutics, Inc. Common Stock Trading Up 4.2%
The stock has a market cap of $1.39 billion, a P/E ratio of -15.96 and a beta of 1.52. The company has a 50 day simple moving average of $22.04 and a 200 day simple moving average of $25.60.
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.12. As a group, sell-side analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.09 earnings per share for the current year.
About Damora Therapeutics, Inc. Common Stock
(
Get Free Report)
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Damora Therapeutics, Inc. Common Stock, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Damora Therapeutics, Inc. Common Stock wasn't on the list.
While Damora Therapeutics, Inc. Common Stock currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.